Intercell vaccine gets U.S. pediatric approval

VIENNA (Reuters) – Austria’s Intercell said on Tuesday it has won U.S. regulatory approval for pediatric use of its Ixiaro vaccine to protect against Japanese Encephalitis (JE), a step it had achieved in Europe in February. “For the first time in nearly two years, a licensed vaccine will now be available to vaccinate traveling children and children of forward-deployed military personal in Asia as well against JE,” Chief Executive Thomas Lingelbach said in a statement, calling the step a key growth element for the product. (Reporting by Michael Shields; Editing by David Cowell)